viernes, 27 de marzo de 2015

ARTERIA Program – A $49.2M investment for patients with or at risk of cardiovascular disease: the Montreal Heart Institute will pilot the #ARTERIA Research Program.

MONTREAL, Feb. 19, 2014 /PRNewswire/ – The Montreal Heart Institute (MHI) announced last week the launch of ARTERIA, a research program


aimed at developing ground-breaking treatments for cardiovascular


diseases, the number one cause of death worldwide. “Once again, the


Montreal Heart Institute and its team of dedicated physicians,


researchers and professionals have established themselves as world


leaders in the fight against heart disease. This program will have


tangible positive effects on patients living with or at risk of


developing cardiovascular disease,” declared Dr. Jean-Claude


Tardif, Director of the MHI Research Centre who will be leading the


project.


The discoveries and innovations that will stem from this unique


program will substantially benefit patients over the medium and long


term by transforming medical practices in the treatment of heart


disease, all while realizing major savings for the health system as a


whole. Among its many benefits, ARTERIA will make it possible to deliver


increasingly personalized medicine and to treat and medicate patients


more effectively, thus saving lives. It is noteworthy that


cardiovascular diseases are the leading cause of hospitalization and


deaths in the world, and that 1.3 million Canadians suffer from various


forms of the illness. Cardiovascular diseases also represent the largest


economic burden of all diagnostic categories with total annual costs of


approximately $22 billion in Canada.


Unprecedented partnership yields major investment of $49.2M


This monumental cutting-edge project has been made possible thanks


to the $49.2 million it has received in funding. Of this amount, $31M


has come from private investments linked to the biopharmaceutical sector


and $18.2M has come from the Government of Quebec. “We are very


proud at the Montreal Heart Institute Research Centre to have succeeded


in attracting to this research program such key stakeholders as the


Quebec Government, Universite de Montreal, and the world’s most


innovative pharmaceutical companies, so that our patients may benefit


from the fruits of this important research,” added Dr. Tardif.


ARTERIA will also lead to the creation of 150 new direct, high-skilled


jobs.


The announcement was made in the presence of Quebec Premier, Pauline


Marois, Ministers Nicolas Marceau, Jean-Francois Lisee and Elaine


Zakaib, Montreal Mayor, Denis Coderre, and representatives of


international pharmaceutical companies. The program’s main private


partners attending the event were eager to praise the MHI Research


Centre’s initiative in establishing this innovative project. In


doing so, they attested to the Institute’s indisputable leadership


on the world stage.


“Through our collaboration, we will be able to combine the


MHI’s worldwide network of scientific and medical research with our


capabilities in translational medicine and clinical development. For


this reason, to Hoffmann-La Roche Ltd, the Montreal Heart Institute is


unequivocally a world-class Quebec institution,” noted Ronnie


Miller, President and Chief Executive Officer of Hoffmann-La Roche Ltd.


Canada.


Frederic Fasano, Canadian CEO of major ARTERIA partner Servier


Canada Inc., for his part underscored the long-standing collaboration


between the two organizations: “Our collaboration with the Montreal


Heart Institute began over 15 years ago. It has been extremely


productive in terms of research and innovation, case in point being a


medication to treat patients with heart failure which was largely


developed within the walls of the Institute. To work with the Montreal


Heart Institute is to work alongside cardiologists and researchers of


one of North America’s top cardiology centres.”


Lastly, major partner MedImmune (a subsidiary of AstraZeneca)


stressed the uniqueness of the MHI and its model. “In taking part


in the ARTERIA program, AstraZeneca, like all other public and private


partners and all patients, will benefit from the internationally


outstanding facility that is the Montreal Heart Institute. The Institute


is the only one to offer an integrated model that runs the gamut from


genetics, to cellular analysis, to major clinical studies. The Montreal


Heart Institute is simply the only centre of its kind in the


world,” added Dr. Fouzia Laghrissi-Thode, Global Vice-President in


charge of AstraZeneca’s Cardiovascular and Metabolic division.


Dr. Guy Breton, Rector of the Universite de Montreal, to which MHI


is affiliated, was thrilled about the announcement. “We are very


proud of the three Universite de Montreal research teams that received


funding as part of this new program. I especially congratulate Dr.


Tardif and his team at the Montreal Heart Institute who are set to lead


a research program that is innovative from every standpoint. On this


Valentine’s Day, which calls to mind the importance of the heart, I


am delighted to know that researchers of such high calibre will have


access to resources and partners that will enable them to develop new


avenues to improve heart health.”


The product of a vast and diversified partnership, ARTERIA has also


been made possible by the significant contribution and tangible support


of the following partners: Valeant Canada, Pharmascience Inc., Thrasos


Therapeutics Inc., Pfizer Canada Inc., Spartan Bioscience Inc., and the


Montreal Heart Institute Foundation.


To view the photo gallery:


http://ift.tt/1eO9GRQ


Founded by Dr. Paul David, The Montreal Health Institute is


celebrating its 60th anniversary in 2014. This commemorative year will


be the occasion to highlight the remarkable achievements in patient


care, research, prevention and teaching that have led the MHI to rise to


the ranks of the top cardiology centres in the world. Montreal-born and


internationally renowned, the Montreal Heart Institute has for the past


60 years brought together impassioned experts who are devoted to pushing


the boundaries of medicine in order to offer exceptional


ultra-specialized care.


About the Montreal Heart Institute: www.icm-mhi.org.


http://ift.tt/1KDUVoc


@ICMtl


SOURCE MONTREAL HEART INSTITUTE


The post ARTERIA Program – A $49.2M investment for patients with or at risk of cardiovascular disease: the Montreal Heart Institute will pilot the #ARTERIA Research Program. appeared first on Health with Beauty.






from WordPress http://ift.tt/19XcP7R

via IFTTT

No hay comentarios.:

Publicar un comentario